{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T05:34:19Z","timestamp":1732253659665,"version":"3.28.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"DOI":"10.7759\/cureus.74182","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T01:16:31Z","timestamp":1732238191000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Immune Abnormalities on COVID-19 Vaccine Effectiveness in Infected Patients"],"prefix":"10.7759","author":[{"given":"Yunhui","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanxia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.46563\/1560-9561-2022-25-2-139-146","article-title":"Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. (Article in Russian)","volume":"25","author":"Galitskaya MG","year":"2022","unstructured":"Galitskaya MG, Fisenko AP, Makarova SG. Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. (Article in Russian). Russian Pediatr J. 2022, 25:139-46. 10.46563\/1560-9561-2022-25-2-139-146","journal-title":"Russian Pediatr J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.17816\/brmma508783","article-title":"Epidemiological effectiveness of domestic influenza vaccines in cases with vaccination against a new coronavirus infection in 2022-2023","volume":"25","author":"Lioznov DA","year":"2023","unstructured":"Lioznov DA, Kuzin AA, Zobov AE, et al.. Epidemiological effectiveness of domestic influenza vaccines in cases with vaccination against a new coronavirus infection in 2022-2023. Bull Russian Military Med Acad. 2023, 25:377-86. 10.17816\/brmma508783","journal-title":"Bull Russian Military Med Acad"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2035222","article-title":"COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies","volume":"21","author":"Di Fusco M","year":"2022","unstructured":"Di Fusco M, Lin J, Vaghela S, et al.. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022, 21:435-51. 10.1080\/14760584.2022.2035222","journal-title":"Expert Rev Vaccines"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00648-2","article-title":"Immune response to COVID-19 and mRNA vaccination in immunocompromised individuals: a narrative review","volume":"11","author":"Napuri NI","year":"2022","unstructured":"Napuri NI, Curcio D, Swerdlow DL, Srivastava A. Immune response to COVID-19 and mRNA vaccination in immunocompromised individuals: a narrative review. Infect Dis Ther. 2022, 11:1391-414. 10.1007\/s40121-022-00648-2","journal-title":"Infect Dis Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002505","article-title":"Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients","volume":"135","author":"Song JW","year":"2022","unstructured":"Song JW, Hu W, Shen L, Wang FS. Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients. Chin Med J (Engl). 2022, 135:2656-66. 10.1097\/CM9.0000000000002505","journal-title":"Chin Med J (Engl)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee AR","year":"2022","unstructured":"Lee AR, Wong SY, Chai LY, et al.. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022, 376:e068632. 10.1136\/bmj-2021-068632","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01087-w","article-title":"The immune response to SARS-CoV-2 in people with HIV","volume":"21","author":"H\u00f6ft MA","year":"2024","unstructured":"H\u00f6ft MA, Burgers WA, Riou C. The immune response to SARS-CoV-2 in people with HIV. Cell Mol Immunol. 2024, 21:184-96. 10.1038\/s41423-023-01087-w","journal-title":"Cell Mol Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-08-098258-8.00025-0","article-title":"Chapter 14.1 - Layered double hydroxides (LDH)","author":"Forano C","year":"2013","unstructured":"Forano C, Costantino U, Pr\u00e9vot V, Gueho CT. Chapter 14.1 - Layered double hydroxides (LDH). Developments in Clay Science. Elsevier, Amsterdam, Netherlands; 2013. 5:745-82. 10.1016\/B978-0-08-098258-8.00025-0"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202100002","article-title":"Proteomic and metabolomic investigation of serum lactate dehydrogenase elevation in COVID-19 patients","volume":"21","author":"Yan H","year":"2021","unstructured":"Yan H, Liang X, Du J, et al.. Proteomic and metabolomic investigation of serum lactate dehydrogenase elevation in COVID-19 patients. Proteomics. 2021, 21:e2100002. 10.1002\/pmic.202100002","journal-title":"Proteomics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2006.00033.x","article-title":"C-reactive protein (CRP)-lowering agents","volume":"24","author":"Prasad K","year":"2006","unstructured":"Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006, 24:33-50. 10.1111\/j.1527-3466.2006.00033.x","journal-title":"Cardiovasc Drug Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.04.035","article-title":"Lactate dehydrogenase in sickle cell disease","volume":"458","author":"Stankovic Stojanovic K","year":"2016","unstructured":"Stankovic Stojanovic K, Lionnet F. Lactate dehydrogenase in sickle cell disease. Clin Chim Acta. 2016, 458:99-102. 10.1016\/j.cca.2016.04.035","journal-title":"Clin Chim Acta"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa1103","article-title":"C-reactive protein and clinical outcomes in patients with COVID-19","volume":"42","author":"Smilowitz NR","year":"2021","unstructured":"Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021, 42:2270-9. 10.1093\/eurheartj\/ehaa1103","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1831383","article-title":"D-dimer level in COVID-19 infection: a systematic review","volume":"13","author":"Rostami M","year":"2020","unstructured":"Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol. 2020, 13:1265-75. 10.1080\/17474086.2020.1831383","journal-title":"Expert Rev Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12467","article-title":"Efficacy evaluation of D-dimer and modified criteria in overt and nonovert disseminated intravascular coagulation diagnosis","volume":"38","author":"Li WJ","year":"2016","unstructured":"Li WJ, Sha M, Ma W, Zhang ZP, Wu YJ, Shi DM. Efficacy evaluation of D-dimer and modified criteria in overt and nonovert disseminated intravascular coagulation diagnosis. Int J Lab Hematol. 2016, 38:151-9. 10.1111\/ijlh.12467","journal-title":"Int J Lab Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102473","article-title":"Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience","volume":"112","author":"Sun Y","year":"2020","unstructured":"Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, Wang FS. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. J Autoimmun. 2020, 112:102473. 10.1016\/j.jaut.2020.102473","journal-title":"J Autoimmun"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5276.21.06170-X","article-title":"Plasma D-dimer : a promising indicator of COVID-19 infection severity or only an acute phase reactant","author":"Han\u00e7erli T\u00f6r\u00fcn S","year":"2021","unstructured":"Han\u00e7erli T\u00f6r\u00fcn S, Kaba \u00d6, Sari Yanartas M, et al.. Plasma D-dimer : a promising indicator of COVID-19 infection severity or only an acute phase reactant. Minerva Pediatr (Torino). 2021, 10.23736\/S2724-5276.21.06170-X","journal-title":"Minerva Pediatr (Torino)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.12.023","article-title":"D-dimer as a potential biomarker for disease severity in COVID-19","volume":"40","author":"Ozen M","year":"2021","unstructured":"Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M, Senol H. D-dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021, 40:55-9. 10.1016\/j.ajem.2020.12.023","journal-title":"Am J Emerg Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121430-20201123-00719","article-title":"Chinese expert consensus on diagnosis and management of immunosuppression in sepsis. (Article in Chinese)","volume":"32","author":"Shock and Sepsis Society of the Chinese Research Hospital Association","year":"2020","unstructured":"Shock and Sepsis Society of the Chinese Research Hospital Association, Critical Care Medicine Society of the Chinese People's Liberation Army, Critical Care Immunotherapy Research Group, Wu J, Luan Y, Ke L. Chinese expert consensus on diagnosis and management of immunosuppression in sepsis. (Article in Chinese). Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020, 32:1281-9. 10.3760\/cma.j.cn121430-20201123-00719","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102154","article-title":"Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study","volume":"63","author":"Peng K","year":"2023","unstructured":"Peng K, Li X, Yang D, et al.. Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. EClinicalMedicine. 2023, 63:102154. 10.1016\/j.eclinm.2023.102154","journal-title":"EClinicalMedicine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11030662","article-title":"Adverse hematological effects of COVID-19 vaccination and pathomechanisms of low acquired immunity in patients with hematological malignancies","volume":"11","author":"Yazdani AN","year":"2023","unstructured":"Yazdani AN, DeMarco N, Patel P, Abdi A, Velpuri P, Agrawal DK, Rai V. Adverse hematological effects of COVID-19 vaccination and pathomechanisms of low acquired immunity in patients with hematological malignancies. Vaccines (Basel). 2023, 11:662. 10.3390\/vaccines11030662","journal-title":"Vaccines (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4161\/hv.32247","article-title":"Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy","volume":"10","author":"Lee KY","year":"2014","unstructured":"Lee KY, Tsai MS, Kuo KC, et al.. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother. 2014, 10:3700-10. 10.4161\/hv.32247","journal-title":"Hum Vaccin Immunother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000005229","article-title":"Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with tocilizumab in a randomized controlled trial","volume":"50","author":"Tom J","year":"2022","unstructured":"Tom J, Bao M, Tsai L, et al.. Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with tocilizumab in a randomized controlled trial. Crit Care Med. 2022, 50:398-409. 10.1097\/CCM.0000000000005229","journal-title":"Crit Care Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108550","article-title":"Inflammatory Response in COVID-19 Depending on the Severity of the Disease and the Vaccination Status","volume":"24","author":"Trofin F","year":"2023","unstructured":"Trofin F, Nastase EV, Ro\u0219u MF, et al.. Inflammatory Response in COVID-19 Depending on the Severity of the Disease and the Vaccination Status. Int J Mol Sci. 2023, 24:8550. 10.3390\/ijms24108550","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309461-impact-of-immune-abnormalities-on-covid-19-vaccine-effectiveness-in-infected-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T01:16:35Z","timestamp":1732238195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309461-impact-of-immune-abnormalities-on-covid-19-vaccine-effectiveness-in-infected-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.74182","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}